Prevalence of Extended Spectrum β-Lactamase and Antimicrobial Susceptibility Pattern of Clinical Isolates of Pseudomonas from Patients of Khyber Pakhtunkhwa, Pakistan

Table 2

Comparative susceptibility pattern between indoor and outdoor patients.

Antimicrobial agents	Hospitalized patients		Outdoor patients		value
	Sensitive; (%)	Resistant; (%)	Sensitive; (%)	Resistant; (%)
AML	22 (9.48)	210 (90.52)	28 (27.45)	74 (72.55)	<0.001
AMC	45 (19.40)	187 (80.60)	37 (36.27)	65 (63.73)	<0.0001
TZP	132 (56.90)	100 (43.10)	71 (69.61)	31 (30.39)	<0.03
SCF	151 (65.09)	81 (34.91)	80 (78.43)	22 (21.57)	<0.02
CEC	40 (17.24)	192 (82.76)	31 (30.39)	71 (69.61)	<0.006
CAZ	69 (29.74)	163 (70.26)	42 (41.18)	60 (58.82)	<0.041
CRO	76 (32.76)	156 (67.24)	45 (44.12)	57 (55.88)	<0.467
FEP	102 (43.97)	130 (56.03)	60 (58.82)	42 (41.18)	<0.0123
ENX	75 (32.33)	157 (67.67)	42 (41.18)	60 (58.82)	<0.022
GTX	95 (40.95)	137 (59.05)	54 (52.94)	48 (47.06)	<0.05
CIP	108 (46.55)	124 (53.45)	60 (58.82)	42 (41.18)	<0.0388
SPX	128 (55.17)	104 (44.83)	58 (56.86)	44 (43.14)	<0.0427
MXF	134 (57.76)	98 (42.24)	72 (70.59)	30 (29.41)	<0.03
E	35 (15.09)	197 (84.91)	29 (28.43)	73 (71.57)	<0.0137
CLR	88 (37.93)	144 (62.07)	54 (52.94)	48 (47.06)	<0.0106
CN	38 (16.38)	194 (83.62)	24 (23.53)	78 (76.47)	<0.0193
AK	140 (60.34)	92 (39.66)	76 (74.51)	26 (25.49)	<0.01
DO	12 (5.17)	220 (94.83)	22 (21.57)	80 (78.43)	<0.0001
MEM	206 (88.79)	26 (11.21)	98 (96.08)	4 (3.92)	<0.032
IPM	189 (81.47)	43 (18.53)	93 (91.18)	9 (8.82)	<0.0242